Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11/03/2008
Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Waltham, MA – November 3, 2008 -- Interleukin Genetics, Inc. (AMEX:ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at 11:35 am EST. The conference will be held at the New York Palace Hotel in New York.
A live audio webcast of the presentation will be available on the Events section of the Interleukin Genetics website, http://www.ilgenetics.com/content/about-interleukin/eventDetail.jsp/q/id/27. A replay of the presentation will be available on the Company’s website for 14 days following the presentation.
About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX:ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals®, including Ginkoba®, Ginsana® and Venastat® which are sold at the nation’s largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
# # #
Contacts:
Media:
Catherine Cloft
LaVoie Group
978-745-4200 x107
ccloft@lavoiegroup.com
Investor Relations:
Melanie Friedman
Stern Investor Relations
212-362-1200
melanie@sternir.com